financetom
Business
financetom
/
Business
/
BRP Down Over 3% After Q1 Earnings - Here's Why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRP Down Over 3% After Q1 Earnings - Here's Why
May 31, 2024 6:56 AM

BRP Inc. ( DOOO ) shares are trading lower in the premarket session on Friday after the company slashed its FY25 guidance.

The company reported first-quarter adjusted earnings per share of 70 cents, which topped the street view of 66 cents.

BRP reported quarterly revenues of $1.498 billion, above the street view of $1.460 billion.

The company witnessed lower volume across most product lines, driven by decreasing network inventory levels and higher sales programs.

“As the year unfolds, our dealers’ profitability is under more pressure than anticipated given the current macroeconomic context, a more competitive landscape and high interest rates,” said José Boisjoli, President and CEO of BRP.

The decrease, however, was partially offset by a favorable product mix across most product lines and favorable pricing across all product lines.

First quarter gross profit margin percentage decreased by 210 basis points to 23.6% from 25.7% for the three-month period ended April 30, 2023. The decrease was the result of a lower volume sold and higher sales programs.

“For these reasons, we have decided to adjust our production to further reduce network inventory while continuing to maximize retail sales,” Boisjoli added.

Dividend: On May 30, the company declared a quarterly dividend of C$0.21 per share. The dividend will be paid on July 12.

Outlook: BRP sees FY25 revenues of C$8.6 billion to C$8.9 billion (consensus C$9.347 billion), lower than the previously issued guidance of C$9.1 billion to C$9.5 billion. The company sees adjusted earnings per share of C$6-C$7, lower than the prior view of C$7.25 to C$8.25, and against the consensus of C$7.79.

Given its focus on managing network inventory levels, the company expects second quarter normalized EBITDA to be down approximatively mid 20% versus first quarter.

Price Action: DOOO shares are trading lower by 3.56% to $64.00 premarket at last check Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Veeco Instruments Narrows Q4 EPS Outlook, Raises Lower End of Q4 Sales Guidance; Shares Up Pre-Bell
Veeco Instruments Narrows Q4 EPS Outlook, Raises Lower End of Q4 Sales Guidance; Shares Up Pre-Bell
Jan 14, 2025
08:45 AM EST, 01/14/2025 (MT Newswires) -- Veeco Instruments ( VECO ) said Tuesday it now expects Q4 non-GAAP earnings of $0.36 to $0.44 per diluted share, compared with its prior guidance of $0.35 to $0.45. Analysts polled by FactSet are expecting Q4 adjusted EPS of $0.4. The company also said it now expects Q4 revenue of $175 million to...
Dream Residential REIT Renewing Normal Course Issuer Bid and Announces Automatic Securities Purchase Plan
Dream Residential REIT Renewing Normal Course Issuer Bid and Announces Automatic Securities Purchase Plan
Jan 14, 2025
08:45 AM EST, 01/14/2025 (MT Newswires) -- Dream Residential Real Estate Investment Trust (DRR-U.TO) on Tuesday announced that the Toronto Stock Exchange accepted a notice from the company related to it renewing its prior normal course issuer bid for a one year period. Under the bid, the Trust will have the ability to purchase for cancellation up to a maximum...
BRIEF-EMCOR Group Announces Agreement to Acquire Miller Electric Company
BRIEF-EMCOR Group Announces Agreement to Acquire Miller Electric Company
Jan 14, 2025
Jan 14 (Reuters) - EMCOR Group Inc ( EME ): * EMCOR GROUP, INC. ( EME ) ANNOUNCES AGREEMENT TO ACQUIRE MILLER ELECTRIC COMPANY * EMCOR GROUP INC ( EME ) - TO ACQUIRE MILLER ELECTRIC FOR $865 MILLION * EMCOR GROUP INC ( EME ) - TRANSACTION EXPECTED TO BE MODESTLY ACCRETIVE TO EMCOR'S EPS IN 2025 * EMCOR...
Emergent BioSolutions Obtains Commercial Rights to Kloxxado Nasal Spray
Emergent BioSolutions Obtains Commercial Rights to Kloxxado Nasal Spray
Jan 14, 2025
08:43 AM EST, 01/14/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Tuesday that it has obtained exclusive commercial rights in the US and Canada to Hikma Pharmaceuticals' Kloxxado Nasal Spray, an 8 mg naloxone agent approved for the emergency treatment of known or suspected opioid overdose. Financial terms were not disclosed. Under the terms of the six-year agreement,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved